DOI: 10.4244/EIJV12SYA1

Welcome to PCR London Valves 2016: back to the UK

Corrado Tamburino, MD, PhD; Stephan Windecker, MD, PhD; Nicolò Piazza, MD, PhD; Michael Haude, MD, PhD; Bernard Prendergast, DM, FRCP, FESC

The field of transcatheter therapies for valvular heart disease is a never-ending source of technical and device innovation, novel indications and new treatment solutions. The interest of the scientific community in this sub-discipline of interventional cardiology is demonstrated by the extraordinary volume of literature on the field, as well as the variety of national and international meetings, symposia and teaching courses focusing on this topic. The annual PCR London Valves meeting – this year back to its original venue– represents the world’s largest course specifically addressing the rapidly expanding and innovative field of transcatheter therapies for valvular heart disease. The agenda has been uniquely built to update all participants with the latest practical and scientific advances whilst also providing opportunities for Heart Teams to interact, exchange and learn.

The EuroIntervention PCR London Valves supplement, which incorporates a number of papers authored by some of the world’s most prominent physicians in the field, embodies the spirit and content of the meeting. This year’s Supplement has been divided into four sections, each headed by a brief editorial that summarises the rationale and content of the related section in a few lines.

The first section is a brief introduction to the role of imaging in heart valve interventions –an extremely important aspect of our daily activity. Today, interventional cardiologists involved in the management of valvular heart disease must be comfortable and familiar with several imaging modalities, particularly echocardiography and computed tomography. The subsequent three sections are dedicated to aortic, mitral and tricuspid interventions, respectively. Each includes a number of authoritative review articles dealing with “hot topics” and emerging technologies. Special attention has been paid to the mitral and tricuspid devices that carry the most interesting novel elements in the field.

This supplement would not have been possible without the enthusiastic participation and support of many extraordinary colleagues and friends who have shared their knowledge and experience with us all. On behalf of the valve community, we thank you.

Volume 12 Supplement Y
Sep 18, 2016
Volume 12 Supplement Y
View full issue


Key metrics

Suggested by Cory

10.4244/EIJV14SABA1 Sep 7, 2018
Welcome to PCR London Valves 2018: 10th Anniversary Edition
Barbanti M et al
free

10.4244/EIJV10I7A136 Nov 20, 2014
PCR London Valves: a very special year
Windecker S et al
free

10.4244/EIJV13I10A178 Nov 20, 2017
PCR London Valves Innovators Day 2017. Where will valve intervention be in 2025?
Dawkins S et al
free

10.4244/EIJV15I10A154 Nov 15, 2019
2019 – A leap year for valvular heart disease
Tamburino C et al
free

10.4244/EIJV8SQA1 Sep 30, 2012
Welcome to PCR London Valves 2012
Thomas M and Windecker S
free

10.4244/EIJV12I9A179 Oct 20, 2016
EAPCI: the home for the world’s valvular community
Haude M
free

10.4244/EIJV9SSA1 Sep 15, 2013
Welcome to PCR London Valves 2013
Thomas M and Windecker S
free

10.4244/EIJV12SYA2 Sep 18, 2016
Integrated imaging: a new skill for interventional cardiologists
Delgado V and Bax J
free
Trending articles
334.8

State-of-the-Art Review

10.4244/EIJ-D-21-00904 Apr 1, 2022
Antiplatelet therapy after percutaneous coronary intervention
Angiolillo D et al
free
202.75

State-of-the-Art

10.4244/EIJ-D-21-00089 Jun 11, 2021
Intracoronary optical coherence tomography: state of the art and future directions
Ali ZA et al
free
47.45

NEW INNOVATION

10.4244/EIJ-D-15-00467 Feb 20, 2018
Design and principle of operation of the HeartMate PHP (percutaneous heart pump)
Van Mieghem NM et al
free
42.15

State-of-the-Art

10.4244/EIJ-D-25-00896 Apr 6, 2026
Pretreatment with antiplatelet agents in patients undergoing coronary revascularisation
Kaur G et al
free
33.05

State-of-the-Art

10.4244/EIJ-D-25-00874 Jun 1, 2026
TAVI and coronary interventions: indications, technical considerations, and clinical scenarios
Aquino Bruno H et al
free
27.6

Original Research

10.4244/EIJ-D-25-01370 May 21, 2026
Prognostic value of early haemodynamic valve deterioration after TAVI
Trimaille A et al
27.6

Original Research

10.4244/EIJ-D-25-01370 Jun 1, 2026
Prognostic value of early haemodynamic valve deterioration after TAVI
Trimaille A et al
19.5

Original Research

10.4244/EIJ-D-26-00032 May 15, 2026
Glucocorticoids to reduce permanent pacemaker implantation after TAVI: the GLUCO-TAVI randomised trial
Fuertes-Kenneally L et al
X

PCR
Impact factor: 9.2
2025 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2026)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2026 Europa Group - All rights reserved